| Literature DB >> 31872476 |
Oliver Pfaar1, Ioana Agache2, Frédéric de Blay3, Sergio Bonini4, Adam M Chaker5, Stephen R Durham6,7, Radoslaw Gawlik8, Peter W Hellings9,10,11, Marek Jutel12,13, Jörg Kleine-Tebbe14, Ludger Klimek15, Matthias V Kopp16,17, Andreas Nandy18, Ronald L Rabin19, Ronald van Ree20, Harald Renz21, Graham Roberts22,23, Anne-Marie Salapatek24, Carsten B Schmidt-Weber25,26, Mohamed H Shamji6,7, Gunter J Sturm27,28, J Christian Virchow29, Ulrich Wahn30, Christoph Willers18, Petra Zieglmayer31, Cezmi A Akdis32,33.
Abstract
The seventh "Future of the Allergists and Specific Immunotherapy (FASIT)" workshop held in 2019 provided a platform for global experts from academia, allergy clinics, regulatory authorities and industry to review current developments in the field of allergen immunotherapy (AIT). Key domains of the meeting included the following: (a) Biomarkers for AIT and allergic asthma; (b) visions for the future of AIT; (c) progress and data for AIT in asthma and the updates of GINA and EAACI Asthma Guidelines (separated for house dust mite SCIT, SLIT tablets and SLIT drops; patient populations) including a review of clinically relevant endpoints in AIT studies in asthma; (d) regulatory prerequisites such as the "Therapy Allergen Ordinance" in Germany; (e) optimization of trial design in AIT clinical research; (f) challenges planning and conducting phase III (field) studies and the future role of Allergen Exposure Chambers (AEC) in AIT product development from the regulatory point of view. We report a summary of panel discussions of all six domains and highlight unmet needs and possible solutions for the future.Entities:
Keywords: allergen exposure chamber; allergen immunotherapy; allergic asthma; biomarker; clinical trials
Mesh：
Substances：
Year: 2019 PMID： 31872476 DOI： 10.1111/all.14077
Source DB: PubMed Journal: Allergy ISSN： 0105-4538 Impact factor: 13.146